- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Blue Cross of California now known as Anthem Blue Cross
Blue Cross of California, one of the state’s largest health plans, has changed its name to Anthem Blue Cross, the San Francisco Business Times reports. Anthem Blue Cross has 8.4 million members in California.
Blue Cross of California, one of the state’s largest health plans, has changed its name to Anthem Blue Cross, the San Francisco Business Times reports. Anthem Blue Cross has 8.4 million members in California.
“We are taking on the Anthem Blue Cross brand since it more effectively symbolizes what our plans represent: the security of Anthem's heritage with the strength and stability of Blue Cross,” Peggy Hinz, public relations director, corporate communications, Anthem Blue Cross, tells Managed Healthcare Executive.
Hinz explains that the company wanted to introduce Anthem Blue Cross to its members and the community at large and at the same time share some of the efforts it has made over recent years to contribute to making communities stronger and healthier. “Two examples of this are our funding of community colleges to help strengthen their nursing programs and our commitment to helping in the fight against childhood obesity,” she says.
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More
